However, it should be emphasized that new biomarkers such as ST2, IL-33, adrenomedullin, copeptin, GDF-15 and galectin-3, despite promising results, have not been included in the European Society of Cardiology guidelines as an element of HF management [1,5]. The gene discussed is ADM; the disease is hydrops fetalis.